Digoxin Toxicity

Digoxin toxicity is a clinical syndrome caused by excessive serum concentrations of the cardiac glycoside digoxin, manifesting as a spectrum of gastrointestinal, neurologic, and cardiac disturbances due to the drug's narrow therapeutic window.

Also Called

• Digitalis toxicity
• Digitalis poisoning
• Digoxin overdose

Classification

Digoxin toxicity is classified along two axes: nature of exposure and severity. The nature of exposure is categorized as acute (single large ingestion), chronic (gradual accumulation, often with renal impairment), or acute-on-chronic (overdose in a patient on maintenance therapy) ^[1]A1c. Severity ranges from mild (non-specific symptoms) to life-threatening (bradyarrhythmias, hyperkalemia, hemodynamic instability) ^[1]A1c[14]D5. The following table summarizes the classification:

Key Terminology

• Serum digoxin concentration (SDC): The measured level of digoxin in blood, typically sampled ≥6-8 hours after a dose. A toxic threshold is variably defined; most consensus targets a therapeutic range of 0.5-0.9 ng/mL, with levels ≥1.2 ng/mL associated with increased mortality ^[7]D5[8]D5. Levels >2 ng/mL are considered frank toxicity ^[10]C4.
• Digoxin immune Fab (Digoxin-Fab): Antibody fragments that bind free digoxin, used for life-threatening toxicity ^[1]A1c[14]D5.
• Life-threatening toxicity: Presence of severe bradyarrhythmias, high-grade AV block, ventricular tachycardia/fibrillation, or serum potassium >5.0 mmol/L in the setting of digoxin excess ^[1]A1c[14]D5.

Clinical Significance

Despite a decline in prescribing, digoxin toxicity remains a persistent clinical challenge because its nonspecific symptoms (e.g., nausea, confusion, visual changes) are often mistaken for other conditions, delaying diagnosis and treatment ^[1]A1c. Hospitalizations for toxicity, though decreasing, still carry a 30-day mortality of approximately 10% ^[6]B2b.

Hand-off to Epidemiology and Risk Factors

Understanding the classification of exposure type and severity is essential for risk stratification. The following section examines the epidemiology and the patient-specific factors, such as renal dysfunction, older age, and drug interactions, that predispose to digoxin toxicity.

Pearl: When evaluating a patient on digoxin, always classify the toxicity as acute, chronic, or acute-on-chronic, this guides the decision to use Digoxin-Fab and the dosing strategy.

The preceding classification underscores that digoxin toxicity is not a relic of past prescribing; it persists as a cause of preventable morbidity. This section examines who is affected and what drives the risk.

Incidence and Demographics

In the United States, an estimated 5156 emergency department (ED) visits for digoxin toxicity occur annually (95% CI 2663-7648), with 78.8% (95% CI 73.5%-84.1%) resulting in hospitalization ^[23]B2c. In the Netherlands, the incidence of hospitalization for digoxin intoxication is 48.5 per 100,000 prescriptions (95% CI 45.9-51.2), corresponding to 1.94 admissions per 1000 treatment-years ^[33]B2b. The rate of ED visits per 10,000 outpatient prescription visits among patients ≥85 years is twice that of patients 40-84 years (rate ratio 2.4; 95% CI 1.2-5.0). Women have a 2.3-fold higher rate than men (95% CI 1.1-4.7) ^[23]B2c; in the Netherlands, women have a 1.4-fold higher risk (95% CI 1.3-1.6) ^[33]B2b.

Temporal Trends

The public health burden of digoxin toxicity declined dramatically from 1991 to 2004 in both the United States and the United Kingdom ^[34]B2c. However, from 2005 to 2010, estimated annual ED visits and hospitalizations remained relatively constant ^[23]B2c. Digoxin use decreased from 31.4% to 23.5% of heart failure admissions between 2001 and 2004, yet the number of toxic exposures requiring hospitalization did not decline ^[32]D5.

Risk Factors

Several modifiable and non-modifiable factors increase the risk of digoxin toxicity:

• Recent hospitalization: Patients hospitalized in the prior 2 months have a 4.25-fold increased risk of subsequent digoxin toxicity-related hospitalization (IRR 4.25; 95% CI 1.95-9.27) ^[22]B2b.
• Co-prescription of trimethoprim-sulfamethoxazole (TMP-SMX): Compared with amoxicillin , the 30-day risk of a hospital encounter for digoxin toxicity is nearly 6-fold higher (weighted RR 5.71; 95% CI 3.19-10.24; NNH 256) ^[4]B2b.
• Diabetes: Suspected digoxin toxicity occurred in 6.5% of digoxin-treated patients with diabetes versus 5.8% without; hospitalization for toxicity was 1.4% versus 0.8% ^[21]A1b.
• Renal impairment: Creatinine clearance <32 mL/min was an independent predictor of toxicity (plasma digoxin ≥0.9 ng/mL) in a machine-learning model ^[9]B3b.
• Daily digoxin dose ≥1.6 µg/kg: Independently predicted toxicity in the same model ^[9]B3b.
• ABCB1 gene variants: Homozygous T allele carriers of C1236T (HR 1.90; 95% CI 1.09-3.30), G2677T (HR 1.89; 95% CI 1.10-3.24), and C3435T (HR 1.72; 95% CI 1.03-2.87) have increased risk of sudden cardiac death while taking digoxin ^[24]B2b.
• Concomitant negative chronotropes: Use of beta-blockers or calcium channel blockers (OR 13.1; 95% CI 1.5-113) and potassium-sparing medications (OR 17.1; 95% CI 2.0-147) were associated with digoxin-Fab administration in elderly patients with chronic toxicity ^[19]B2b.

Risk Factor Summary

Controversies and Guideline Disagreement

Pearl: The 30-day period following hospital discharge is a high-risk window for digoxin toxicity; consider dose reduction and enhanced monitoring during this time, especially in elderly women with renal impairment.

The risk factors outlined above, renal impairment, advanced age, and polypharmacy, converge on a single cellular target: the Na+/K+-ATPase pump. Digoxin binds to and inhibits the α-subunit of this pump, an action that at therapeutic doses increases myocardial contractility but, when excessive, triggers a cascade of ionic and molecular events culminating in arrhythmias, hyperkalemia, and end-organ dysfunction.

Cellular Mechanism of Toxicity

Inhibition of Na+/K+-ATPase raises intracellular sodium concentration. The Na+/Ca2+ exchanger (NCX), sensing the elevated sodium gradient, reverses its mode and extrudes sodium while importing calcium. The resulting intracellular calcium overload is the central driver of digoxin toxicity. In cardiac myocytes, excess calcium is sequestered into the sarcoplasmic reticulum, leading to spontaneous diastolic calcium release events that generate delayed afterdepolarizations (DADs). When DADs reach threshold, they trigger triggered arrhythmias, most commonly premature ventricular contractions, bidirectional ventricular tachycardia, and atrial tachycardia with block. This mechanism explains why hypokalemia, which further inhibits Na+/K+-ATPase (potassium normally competes with digoxin for the binding site), dramatically potentiates toxicity.

Hyperkalemia in acute digoxin poisoning arises from a different mechanism: widespread inhibition of Na+/K+-ATPase in skeletal muscle shifts potassium from the intracellular to the extracellular space, producing a life-threatening rise in serum potassium without an increase in total body potassium ^[35]D5. In chronic toxicity, hyperkalemia is less prominent but still a marker of severe poisoning.

Molecular Pathways: NF-κB and Calcium Channels

Recent animal work has uncovered a second, amplifying mechanism. In healthy mice, high-dose digoxin (1 or 5 mg/kg/day for seven days) significantly increased myocardial expression of nuclear factor kappa-B (NF-κB) and the voltage-gated L-type calcium channel CaV1.2 ^[17]D5. NF-κB is a transcription factor that promotes inflammatory responses and adverse cardiac remodeling; its activation during digoxin toxicity correlates with increased intracellular calcium levels. The upregulation of CaV1.2 further augments calcium influx, creating a positive-feedback loop that worsens calcium overload and myocardial necrosis. Histologically, the 5 mg/kg/day group showed significantly more severe myocardial necrosis and cellular infiltration ^[17]D5. This NF-κB-CaV1.2 axis may explain why toxicity can occur even at serum digoxin concentrations within the therapeutic range, particularly in patients with underlying inflammation or ischemia.

Drug Interactions and P-glycoprotein

Digoxin is a substrate of the efflux transporter P-glycoprotein (P-gp), which limits intestinal absorption and promotes renal tubular secretion. Drugs that inhibit P-gp, such as the ketolide antibiotic telithromycin, can reduce digoxin elimination in the intestinal lumen and its renal tubular excretion, leading to elevated plasma levels and toxicity ^[37]C4. A case report documented a 58-year-old woman on stable digoxin 0.25 mg/day who developed syncope and elevated digoxin levels after a five-day course of telithromycin; the interaction was rated probable on the Naranjo scale ^[37]C4. Other P-gp inhibitors (e.g., amiodarone , verapamil , quinidine, spironolactone ) carry similar risks and are commonly co-prescribed in heart failure patients.

Differences in Oleander Poisoning

Yellow oleander ( Thevetia peruviana ) and common oleander ( Nerium oleander ) contain cardiac glycosides, thevetins A and B, neriifolin, that share the same Na+/K+-ATPase mechanism as digoxin ^[35]D5. However, important epidemiological and clinical differences exist: oleander poisoning typically occurs in younger patients without preexisting illness or comorbidity, whereas digoxin toxicity predominantly affects elderly patients with renal impairment and polypharmacy ^[35]D5. The arrhythmogenic profile is similar, both cause bradyarrhythmias and tachyarrhythmias, but oleander poisoning more frequently presents with severe hyperkalemia due to the larger glycoside load ^[38]D5. Management principles are identical, with digoxin-specific antibody fragments as the only proven therapy ^[35]D5.

Mechanism Flowchart

Pearl: The core mechanism of digoxin toxicity is intracellular calcium overload from Na+/K+-ATPase inhibition, amplified by NF-κB-mediated upregulation of L-type calcium channels, a vicious cycle that explains why even therapeutic serum levels can be toxic in patients with inflammation, ischemia, or concomitant P-gp inhibitor use.

The clinical manifestations of digoxin toxicity arise directly from its mechanism of action, inhibition of the Na+/K+-ATPase pump leading to intracellular calcium overload and increased vagal tone, and are notoriously nonspecific, often mimicking other illnesses. The presentation varies by acuity (acute vs chronic), patient age, and comorbidities, but a core set of symptoms and signs should prompt immediate consideration.

Presenting Symptoms

• Gastrointestinal: Nausea and vomiting are the most common symptoms, occurring in 36-88% of patients depending on the cohort ^{[5]C4[36]C4[42]C4}. Anorexia, diarrhea, and abdominal pain are also frequent, especially in chronic toxicity ^[44]C4.
• Neurological: Confusion, weakness, dizziness, and visual disturbances (blurred or yellow vision, halos) are classic but often underrecognized. Altered level of consciousness may be the dominant feature in children ^[45]C4.
• Cardiac: Palpitations, syncope, or presyncope reflect underlying arrhythmias. In acute overdose, symptoms typically develop within 2-6 hours; in chronic toxicity, they evolve insidiously over days to weeks ^[1]A1c.

Examination Findings

• Vital signs: Bradycardia is the hallmark. Median heart rate in chronic toxicity is approximately 49 beats/min ^[36]C4; in acute overdose, 41 beats/min ^[5]C4. Hypotension may occur with severe poisoning.
• Cardiac examination: Irregular rhythm ( atrial fibrillation with slow ventricular response, junctional rhythm, or complete heart block). The classic arrhythmia is atrial tachycardia with block, but any bradyarrhythmia or tachyarrhythmia is possible ^[43]C4[45]C4.
• Neurological examination: Lethargy, confusion, or obtundation. Cranial nerve findings (e.g., visual field defects) are less common.
• Laboratory: Hyperkalemia is a critical finding. In chronic toxicity, median potassium is 5.3 mmol/L ^[36]C4; in acute overdose, 5.0 mmol/L ^[5]C4. A potassium >5.0 mEq/L carries prognostic significance ^[41]B3b.

Phenotypic Variants

Red Flags

• Bradycardia + hyperkalemia: This combination strongly predicts fatality even after appropriate Fab administration (86% of deaths in one series) ^[41]B3b.
• Ventricular arrhythmias : Ventricular tachycardia, fibrillation, or torsades de pointes require immediate Fab therapy ^[43]C4.
• Syncope or hemodynamic instability: Indicates severe conduction disturbance or arrhythmia.
• Rapidly rising potassium: In acute overdose, hyperkalemia reflects massive Na+/K+-ATPase inhibition and portends a poor prognosis.

Pearl: The combination of bradycardia (HR <51/min) and hyperkalemia (K >5.0 mEq/L) in chronic digoxin toxicity is a strong predictor of fatality even after appropriate Fab administration; this should trigger immediate aggressive therapy ^{[19]B2b[41]B3b}.

From the clinical presentation of gastrointestinal, neurologic, and cardiac manifestations, the diagnosis of digoxin toxicity is established by integrating serum drug levels, electrocardiographic findings, and laboratory markers of severity. The workup proceeds rapidly because the condition is potentially life-threatening and treatment decisions hinge on objective data.

Serum Digoxin Concentration (Gold Standard)

Serum digoxin concentration is the gold-standard diagnostic test ^[37]C4[43]C4. Levels are measured at presentation to confirm exposure and quantify the degree of toxicity. In acute overdose, levels can be extremely high, one reported case documented a level of 35.6 ng/mL ^[43]C4. Although a specific therapeutic range is not uniformly defined, levels above the accepted therapeutic window (generally 0.5-2.0 ng/mL) raise suspicion, and markedly elevated levels confirm toxicity. The test is widely available and results guide the need for digoxin-specific antibody fragments.

Electrocardiographic Findings

Digoxin toxicity produces a spectrum of characteristic arrhythmias that are often the first clue to the diagnosis. The following table summarizes the key ECG findings reported in the literature:

ECG should be obtained emergently in any patient on digoxin presenting with syncope, palpitations, or bradycardia.

Laboratory Studies

Serum potassium is the most important ancillary laboratory test. In chronic digoxin toxicity, hyperkalemia is a powerful predictor of fatality. A case-control study found that a pre-treatment serum potassium ≥5.0 mEq/L had 92% sensitivity (95% CI 67-99) for death ^[41]B3b. The combination of bradycardia plus hyperkalemia strongly predicted fatality even in patients who received appropriate digoxin-specific antibody fragments ^[41]B3b.

Renal function (serum creatinine) should be assessed because impaired renal clearance predisposes to toxicity, especially when combined with dehydration or interacting drugs ^[40]C4.

Drug interaction screening is essential. Macrolide antibiotics such as telithromycin and clarithromycin inhibit P-glycoprotein-mediated efflux of digoxin, raising serum levels and precipitating toxicity ^[37]C4[40]C4. A careful medication history should include recent antibiotic use.

Diagnostic Algorithm

Step 1: Suspect digoxin toxicity in any patient on digoxin who presents with nausea, vomiting, visual disturbances, weakness, syncope, or arrhythmia. Step 2: Obtain a serum digoxin level, a 12-lead ECG, and a serum potassium concentration. Step 3: If the digoxin level is elevated and the ECG shows a characteristic arrhythmia (e.g., atrial tachycardia with block) or the potassium is ≥5.0 mEq/L, the diagnosis is confirmed. Step 4: If the level is elevated but ECG and potassium are normal, toxicity is still possible, especially with very high levels or typical symptoms. Step 5: If the digoxin level is within the therapeutic range, pursue alternative diagnoses such as other drug-induced bradyarrhythmias, electrolyte disturbances, or primary gastrointestinal illness.

Differential Diagnosis

The differential includes conditions that mimic the bradyarrhythmias, hyperkalemia, or gastrointestinal symptoms of digoxin toxicity:

• Sick sinus syndrome or high-grade AV block from other causes (ischemia, degenerative disease)
• Hyperkalemia from renal failure, potassium-sparing diuretics, or other medications
• Other drug toxicities (beta-blockers, calcium channel blockers, amiodarone )
• Gastroenteritis or metabolic disturbances causing nausea and vomiting
• Cerebrovascular events causing visual or neurologic symptoms

A normal serum digoxin level effectively excludes digoxin toxicity as the primary cause.

Pearl: In chronic digoxin toxicity, a serum potassium ≥5.0 mEq/L is a red flag for impending fatality, it should prompt immediate administration of digoxin-specific antibody fragments regardless of the digoxin level ^[41]B3b.

Once the diagnosis of digoxin toxicity is established, the next step is to stratify the patient's risk for life-threatening arrhythmias to guide the intensity of monitoring and therapy. No single universal severity staging system exists, but several validated tools and clinical factors can inform risk.

Serum Digoxin Levels and Traditional Risk Assessment

Serum digoxin concentration remains the most widely used objective measure, though its feasibility is limited in resource-restricted settings ^[47]B2b. Levels >2.0 ng/mL are generally considered toxic, but toxicity can occur at lower levels, especially with hypokalemia, hypomagnesemia, or renal impairment. In patients with Chagas' cardiomyopathy , median digoxin levels were 1.27 ng/mL, and 45% had abnormal levels, correlating with creatinine and inversely with sodium ^[49]C4. Continuous ECG monitoring for at least 24 hours is recommended, with longer monitoring for severe poisoning ^[35]D5.

Pediatric Risk Nomogram

A multicenter study developed and validated a bedside nomogram to predict serious arrhythmias in children with acute digoxin intoxication ^[47]B2b. The prevalence of serious arrhythmias was 17%. The nomogram combines four factors: age, initial random blood glucose, sodium, and potassium levels. It predicted serious arrhythmias with an accuracy of 96.2% (sensitivity 94.4%, specificity 96.5%) and an area under the curve (AUC) of 0.977 (p < 0.001). Validation yielded an AUC of approximately 81% for the nomogram probability and 98.3% for the predicted probability, indicating performance comparable or superior to serum digoxin level ^[47]B2b.

Genetic Risk Factors

Pharmacogenetic variants in the ABCB1 gene, which encodes P-glycoprotein, modify digoxin bioavailability and toxicity risk. In a population-based cohort, digoxin users who were homozygous T allele carriers of C1236T (HR 1.90; 95% CI 1.09-3.30), G2677T (HR 1.89; 95% CI 1.10-3.24), and C3435T (HR 1.72; 95% CI 1.03-2.87) had a significantly increased risk of sudden cardiac death compared to those with none or one T allele ^[24]B2b. Interaction between these polymorphisms and digoxin use was significant for C1236T and G2677T ^[24]B2b.

Special Populations

In young patients without significant comorbidities, suicidal digoxin poisoning is usually mild to moderate and responds well to conventional treatment; underlying cardiac disease and chronic digoxin use did not affect severity or incidence of lethal dysrhythmia in this group ^[48]C4. Conversely, patients with Chagas' cardiomyopathy and heart failure are at higher risk for toxicity and require close monitoring of digoxin levels ^[49]C4.

Pearl: For pediatric acute digoxin toxicity, the four-factor nomogram (age, glucose, sodium, potassium) outperforms serum digoxin level in predicting serious arrhythmias and can guide early use of digoxin-specific antibody fragments ^[47]B2b.

Once severity is stratified, management proceeds along a time-sensitive pathway anchored by the decision to administer digoxin-specific antibody fragments (digoxin-Fab). The following protocol integrates evidence from the largest available case series, pharmacokinetic modelling, and expert consensus.

Step 1: Initial Assessment and Severity Classification

Classify toxicity as mild (asymptomatic or non-specific symptoms, serum digoxin <2.0 ng/mL), moderate (symptomatic bradycardia, gastrointestinal symptoms, potassium <5.0 mEq/L), or severe (life-threatening arrhythmia, hyperkalemia ≥5.0 mEq/L, haemodynamic instability). The presence of bradycardia plus hyperkalemia (≥5.0 mEq/L) strongly predicts fatality even with appropriate Fab administration ^[41]B3b. All patients with suspected toxicity require continuous ECG monitoring, IV access, and stat serum digoxin, potassium, creatinine, and magnesium.

Step 2: First-Line Intervention, Digoxin-Specific Antibody Fragments

Digoxin-Fab is indicated for life-threatening tachy-bradyarrhythmias, hyperkalemia >6.0 mmol/L, or haemodynamic instability with an elevated digoxin concentration (>2 μg/L or 2.6 nmol/L) ^[53]D5. The EXTRIP workgroup recommends against extracorporeal treatment when Fab is available (1D) ^[51]A1c.

Dosing strategy: In acute poisoning, a titrated approach using repeated low doses (1-2 vials) is safe and reduces total usage by 65-75% compared with calculated full neutralising doses ^[5]C4. The median total dose in the titration group was 4 vials (IQR 2-7.5) ^[5]C4. In chronic poisoning, give 40 mg (1 vial) at a time, repeat after 60 min if no response; 40-120 mg (1-3 vials) is usually sufficient ^[53]D5. For imminent cardiac arrest, a full neutralising dose (10-20 vials) may be justified ^[53]D5.

Step 3: Supportive Care and Monitoring

Correct hypokalemia cautiously (potassium <3.5 mEq/L may worsen arrhythmia). Do not use bicarbonate routinely; it is not indicated for digoxin toxicity. Atropine is often ineffective for bradyarrhythmia. Temporary pacing may be used as a bridge to Fab effect but does not treat the underlying toxicity.

Step 4: Monitoring and Titration

After Fab administration, free digoxin concentration falls to near zero within minutes ^[5]C4. Monitor heart rate, potassium, and ECG every 1-2 hours initially. Rebound of free digoxin >2.6 nmol/L (2 μg/L) occurs in up to 40% of patients but is rarely associated with clinical deterioration ^[5]C4. Repeat Fab dosing if clinical toxicity recurs.

Step 5: Transition to Long-Term Management

Once toxicity resolves (normal heart rate, potassium <5.0 mEq/L, no arrhythmia), reassess the ongoing need for digoxin. Do not restart digoxin without careful evaluation of renal function, drug interactions, and indication. The 2024 expert consensus emphasises considering time of ingestion and nature of exposure (acute, acute-on-chronic, chronic) when planning follow-up ^[1]A1c.

Drug Interactions to Avoid

• Trimethoprim-sulfamethoxazole increases risk of hospital encounter for digoxin toxicity nearly 6-fold (weighted RR 5.71; 95% CI 3.19-10.24; NNH 256) ^[4]B2b. Prescribe an alternative antibiotic when possible.
• Sennosides at average daily dose ≥24 mg increase risk of digoxin toxicity (adjusted OR 1.93; 95% CI 1.27-2.94) ^[50]B3b.
• Macrolides (erythromycin, clarithromycin , azithromycin ) do not significantly increase sudden death risk in digoxin users ^[25]B3b, but clarithromycin can precipitate toxicity via P-glycoprotein inhibition ^[40]C4.

What NOT to Do

• Do not use extracorporeal treatment (hemodialysis, hemoperfusion) for digoxin toxicity when Fab is available ^[51]A1c (1D).
• Do not administer full neutralising doses routinely; titrated dosing is equally effective and far less expensive ^[5]C4.
• Do not restart digoxin after toxicity without addressing modifiable risk factors (renal impairment, drug interactions, supratherapeutic dosing).

Controversies and Guideline Disagreement

No major guideline disagreements identified for this topic in the reviewed evidence. The 2024 expert consensus ^[1]A1c and EXTRIP recommendations ^[51]A1c are concordant on Fab as first-line therapy and against ECTR.

Pearl: In acute digoxin poisoning, titrated low-dose digoxin-Fab (1-2 vials repeated as needed) is as effective as full neutralising doses and reduces cost by 65-75%; in chronic poisoning, 1-3 vials usually suffice ^[5]C4[53]D5.

Once acute digoxin toxicity is stabilized with digoxin-specific antibody fragments (Fab) and supportive care, the transition to long-term management centers on preventing recurrence through careful monitoring, dose adjustment, and elimination of high-risk drug interactions. The median age of patients with toxicity is >65 years (88% in one national database), and the annual rate of emergency department visits for digoxin toxicity remains constant at approximately 5,156 cases per year in the United States, with 78.8% of those resulting in hospitalization ^{[23]B2c[52]B2b}. These figures underscore the need for a systematic, guideline-directed long-term strategy.

Step 1: Identify and Modify Modifiable Risk Factors

Hospitalization itself is a strong risk factor: patients discharged within the past 2 months have a 4.25-fold increased risk of subsequent digoxin toxicity (IRR 4.25; 95% CI 1.95-9.27) ^[22]B2b. Renal impairment, hyperkalemia, and acute renal failure are independent predictors of Fab use (odds ratios 2.1, 2.4, and 2.1, respectively; p<0.0001) ^[52]B2b. Therefore, the long-term plan should include:

• Optimize renal function: monitor serum creatinine and eGFR at each visit.
• Correct electrolyte disturbances: maintain potassium between 4.0 and 5.0 mmol/L; hypokalemia worsens cardiac glycoside toxicity, and hyperkalemia is life-threatening ^[35]D5.
• Avoid precipitants: address acute illness, dehydration, and new medications that can impair renal function or alter digoxin pharmacokinetics.

Step 2: Eliminate or Monitor High-Risk Drug Interactions

Drug-drug interactions are a major cause of preventable digoxin toxicity. A population-based study found that the combined use of sennosides (a common laxative) and digoxin was associated with a 1.61-fold increased risk of digoxin toxicity (95% CI 1.15-2.25), and a dose ≥24 mg daily raised the risk to 1.93 (95% CI 1.27-2.94) ^[50]B3b. The mechanism is likely hypokalemia and increased digoxin absorption due to accelerated gastrointestinal transit ^[11]C4. Similarly, macrolide antibiotics dramatically increase digoxin toxicity risk:

Do not prescribe clarithromycin with digoxin; if unavoidable, reduce digoxin dose by 50% and monitor serum digoxin levels closely ^[56]B3b. For macrolides, azithromycin carries the lowest risk, but still warrants monitoring ^[55]B3b. For constipation, avoid sennosides; if needed, use a non-interacting laxative such as polyethylene glycol ^[50]B3b. Other drug classes that may increase risk include spironolactone (via potassium elevation and renal impairment) and calcium channel blockers (e.g., verapamil ), which reduce digoxin clearance ^[36]C4.

Step 3: Optimize Digoxin Dosing and Monitoring Serum Levels

After an episode of toxicity, reassess the indication for digoxin. The DIG trial showed that digoxin reduces heart failure hospitalizations (HR 0.69-0.79) but does not reduce mortality ^[21]A1b. In symptomatic rheumatic heart disease , digoxin 0.125-0.25 mg once daily reduced the composite of death or heart failure (HR 0.82; 95% CI 0.70-0.97) with low toxicity rates (1.1% discontinued due to suspected toxicity) ^[2]A1b.

If digoxin is continued, adhere to these principles:

• Use the lowest effective dose: start at 0.125 mg daily in patients with preserved renal function; reduce to 0.125 mg every other day if eGFR <30 mL/min.
• Maintain serum digoxin concentration <2.0 ng/mL. In a national surveillance study, 95.8% of ED visits for digoxin toxicity had serum levels ≥2.0 ng/mL ^[23]B2c. Maternal side effects (digestive symptoms) occur above 2 ng/mL and reverse within 48 hours of dose reduction ^[10]C4.
• Monitor renal function and potassium at each visit, and check digoxin levels whenever a new interacting drug is added or when renal function declines ^[27]C4.
• Be aware of the post-hospitalization window: the risk of toxicity is highest in the first 2 months after discharge; schedule a follow-up visit and serum level check within 2 weeks of discharge ^[22]B2b.

Step 4: Patient Education and Follow-Up

Educate patients about symptoms of toxicity (nausea, vomiting, visual disturbances, palpitations) and the need to avoid non-prescribed laxatives, herbal products (e.g., senna , Cassia angustifolia ), and antibiotics without prescriber knowledge ^{[11]C4[12]C4[50]B3b}. Provide a written list of medications to avoid. For patients with diabetes, digoxin toxicity is more common (6.5% vs 5.8% in the DIG trial) and hospitalization for toxicity is higher (1.4% vs 0.8%) ^[21]A1b.

What NOT to Do

• Do not use extracorporeal treatment (ECTR) for digoxin toxicity. The EXTRIP workgroup recommends against ECTR in severe poisoning when Fab is available (1D) and even when Fab is unavailable (2D), because digoxin is only slightly dialyzable and ECTR does not improve outcomes ^[51]A1c.
• Do not restart digoxin at a higher dose after toxicity; the majority of cases are chronic, and the risk of recurrence is high ^[36]C4.
• Do not combine digoxin with clarithromycin or high-dose sennosides; if unavoidable, reduce digoxin dose and monitor levels daily ^[56]B3b.

Controversies and Guideline Disagreement

No major guideline disagreements were identified in the reviewed evidence. The 2024 Expert Consensus on digoxin toxicity ^[1]A1c provides a systematic framework for diagnosis and management, but does not give specific long-term recommendations beyond acute treatment. The EXTRIP recommendations ^[51]A1c are consistent across all clinical scenarios: ECTR is not indicated.

Pearl: After an episode of digoxin toxicity, the cornerstone of long-term prevention is eliminating drug interactions (especially macrolides and sennosides) and maintaining serum digoxin concentration below 2.0 ng/mL through careful monitoring of renal function and potassium, with a mandatory follow-up visit within 2 weeks of hospital discharge ^{[22]B2b[23]B2c[50]B3b[55]B3b}.

When toxicity is recognized despite preventive monitoring, definitive intervention centers on the timely administration of digoxin-specific antibody fragments (Digoxin-Fab) and, in selected cases, temporary cardiac pacing. The expert consensus recommends Digoxin-Fab for life-threatening exposure to decrease risk of death ^[1]A1c.

Step 1: Indications for Digoxin-Fab

Digoxin-Fab is indicated for life-threatening arrhythmias (e.g., ventricular tachycardia, high-degree AV block), hemodynamic instability, and hyperkalemia >5.5 mmol/L ^[1]A1c[57]C4. In a retrospective series, Fab was administered more commonly when heart rate was <51/min or serum potassium >5.0 mmol/L; patients receiving Fab were more likely to be on β-blockers or calcium-channel blockers (95% vs 61%; OR 13.1; 95% CI 1.5-113) and to have elevated creatinine (76% vs 42%; OR 8.2; 95% CI 1.9-34) ^[19]B2b.

Step 2: Dosing Strategies

Two dosing approaches are described:

• Traditional bolus: 5-20 vials as a single dose, calculated from ingested dose or measured serum concentration.
• Titrated dosing: 1-2 vials repeated at bedside, guided by clinical response (heart rate, potassium, rhythm). In a prospective observational study (n=23), the titrated approach used a median total dose of 4 vials (IQR 2-7.5), which was 25% and 35% of the predicted bolus doses based on ingestion or serum concentration, respectively ^[5]C4. Median heart rate increased by 19 beats/min post-Fab, and potassium decreased by 0.3 mmol/L; no deaths occurred ^[5]C4. The consensus supports titrated dosing for acute poisoning to reduce total usage and cost without compromising safety ^[1]A1c[5]C4.

Step 3: Temporary Cardiac Pacing

In patients with severe bradycardia or high-degree AV block that does not respond to atropine or Digoxin-Fab, temporary transvenous pacing may be considered. However, pacing alone does not address the underlying intoxication and may provoke ventricular arrhythmias in the irritable myocardium. The evidence for pacing in digoxin toxicity is limited to case reports; no controlled data exist. Atropine may be used as a temporizing measure ^[57]C4.

Step 4: What NOT to Do

• Hemodialysis is ineffective for removing digoxin due to its large volume of distribution ^[57]C4.
• Calcium administration for hyperkalemia remains controversial; it may be used cautiously when hyperkalemia is life-threatening, but it can potentiate digoxin toxicity ^[57]C4.

Pearl: Titrated, low-dose Digoxin-Fab (1-2 vials repeated) is as effective as traditional bolus dosing for acute digoxin poisoning, reducing total antibody use by 65-75% while maintaining safety, reserve empiric pacing only for refractory, life-threatening bradyarrhythmias.

The recognition that digoxin's narrow therapeutic window could produce life-threatening arrhythmias and hyperkalemia drove the development of specific antidotes and a fundamental shift toward lower dosing. The therapeutic timeline of digoxin toxicity is a story of learning from harm: early reliance on withdrawal and supportive care gave way to activated charcoal for enhanced elimination, then to digoxin-specific antibody fragments (Fab) as the definitive antidote, and finally to a modern paradigm of concentration-guided low-dose therapy that minimizes toxicity while preserving benefit.

Early Era: Withdrawal and Supportive Care

For much of the 20th century, the mainstay of digoxin toxicity management was drug discontinuation, cardiac monitoring, and treatment of arrhythmias with lidocaine or phenytoin . Hyperkalemia, a hallmark of acute severe toxicity, was managed with insulin-glucose and bicarbonate, but mortality remained high, especially in patients with renal failure ^[68]C4. The observation that serum digoxin concentrations (SDC) >3 ng/mL did not invariably produce symptoms, only 2 of 54 asymptomatic patients in one series developed definite toxicity, led to the insight that clinical status, not the number alone, should guide intervention ^[67]B2b.

Activated Charcoal: Enhancing Elimination

In the 1980s, multiple-dose activated charcoal emerged as a strategy to interrupt enterohepatic recirculation and accelerate digoxin clearance. A randomized crossover study in healthy subjects showed that 225 g of activated charcoal over 40 hours increased digoxin clearance by 47% (from 12.2 to 18.0 L/hr) and shortened the terminal half-life from 36.5 to 21.5 hours ^[60]A1b. The effect was even more pronounced in a patient with chronic renal failure, where clearance rose from 3.6 to 10.1 L/hr ^[70]A1b. Charcoal became a standard adjunct, particularly in patients with renal impairment, though its utility in those with normal renal function was limited ^[70]A1b.

Digoxin-Specific Fab Fragments: The Definitive Antidote

The development of digoxin immune Fab (ovine) in the 1970s-1980s revolutionized treatment. Polyclonal antibody fragments bind digoxin with high affinity, forming inactive complexes that are renally excreted ^[71]D5. Marchlinski et al. established Fab as the treatment of choice for any digoxin-toxic arrhythmia with hemodynamic compromise and for hyperkalemia due to acute severe toxicity ^[72]D5. Fab fragments reverse toxicity within minutes to hours, dramatically reducing mortality from what was once a frequently fatal poisoning. Their use is now standard for life-threatening digoxin toxicity, though cost and availability remain barriers.

The DIG Trial and the Shift to Low-Dose Therapy

The Digitalis Investigation Group (DIG) trial, published in 1997, was the pivotal randomized study of digoxin in heart failure with reduced ejection fraction (HFrEF). Over a median of 37 months, digoxin had no effect on all-cause mortality (34.8% vs. 35.1%, p=0.80) but significantly reduced HF hospitalizations ^[58]A1b. Subsequent analyses revealed a strong concentration-response relationship: SDCs of 0.5-0.9 ng/mL were associated with lower mortality and hospitalization, whereas levels ≥1.2 ng/mL markedly increased risk ^[7]D5. This finding, confirmed in the ARISTOTLE trial where each 0.5 ng/mL increase in SDC raised mortality by 19%, drove a fundamental shift from traditional dosing (0.25 mg daily) to lower, concentration-targeted regimens ^[7]D5.

Drug Interactions and Toxicity Prevention

Recognition of drug interactions that elevate SDC was another critical evolution. Quinidine was shown to increase SDC by more than 50% in seven of nine patients (mean from 1.43 to 2.61 nmol/L) ^[69]B2b. Diltiazem increased the area under the curve by 51% and steady-state concentration by 50% ^[64]A1b. Omeprazole increased bioavailability of unchanged digoxin by 13.4% ^[61]A1b, and alprazolam 1 mg/day produced a more pronounced increase in elderly patients, with one case of clinical toxicity ^[59]A1b. These discoveries led to routine monitoring of SDC when interacting drugs are initiated or withdrawn, and to the use of alternative agents (e.g., disopyramide instead of quinidine) ^[69]B2b.

Modern Controversies and the Mortality Signal

In the 2000s, large observational studies (TREAT-AF, AFFIRM) reported an association between digoxin use and increased mortality in atrial fibrillation , fueling skepticism. However, contemporary analyses, including the RATE-AF randomized trial and propensity-matched studies, demonstrate that this signal is largely due to confounding by indication and prescription bias, not intrinsic toxicity ^[7]D5. When SDC is maintained ≤0.9 ng/mL, digoxin does not increase mortality and remains a safe option for rate control in patients with HFrEF, hypotension, or β-blocker intolerance ^[7]D5. The 2024 ESC guidelines assign digoxin a Class IIa recommendation for long-term rate control in AF with HF ^[7]D5.

Pearl

The evolution of digoxin therapy is a cautionary tale: the drug's narrow therapeutic window and concentration-dependent toxicity were recognized only after decades of use, leading to the modern emphasis on low-dose therapy (0.5-0.9 ng/mL) and Fab fragments for severe toxicity. The DIG trial's neutral mortality but morbidity benefit, combined with the debunking of the observational mortality signal, has solidified digoxin's role as a second-line but valuable agent when used with disciplined monitoring.

Pearl: Drug interactions (quinidine, diltiazem, omeprazole, alprazolam) can dramatically elevate SDC and require proactive monitoring and dose adjustment.

Mortality and Morbidity

Digoxin toxicity remains a significant clinical problem, with annual deaths reported in the United States ranging from 18 to 36 per year (2012–2020 data from the National Poison Control Center) ^[8]D5. This mortality rate is substantially higher than that of other narrow therapeutic index drugs such as lithium (1–7 deaths/year) and warfarin (0–2 deaths/year) ^[8]D5. In a population-based study of older adults (≥65 years) taking digoxin, the risk of sudden death within 14 days of exposure to macrolide antibiotics was elevated, with an odds ratio of 1.32 (95% CI 1.03–1.69) for clarithromycin compared to cefuroxime ^[25]B3b. Chronic digoxin toxicity carries a case fatality rate that correlates with pre-treatment serum potassium; in a case-control study, all 13 fatalities had a median serum potassium of 5.1 mEq/L (range 4.1–7.0) versus 4.1 mEq/L (range 3.5–4.6) in survivors ^[41]B3b. Among patients with systemic light-chain (AL) amyloidosis on digoxin, significant arrhythmias developed in 11% of patients, almost exclusively in those with advanced cardiac involvement, and 8% died from arrhythmia ^[18]C4.

Cardiac Arrhythmias

Digoxin toxicity can produce a wide variety of bradyarrhythmias and tachyarrhythmias ^[35]D5. Common electrocardiographic manifestations include atrial tachycardia with block, accelerated junctional rhythm, second- or third-degree atrioventricular block, and bidirectional ventricular tachycardia ^[73]D5. In a series of patients with elevated digoxin levels (≥1.2 ng/mL) presenting to an emergency department, 68.6% were women (mean age 76.1 years), and the most common ECG findings were bradycardia (heart rate <60/min) and atrial fibrillation with slow ventricular response ^[54]C4. The presence of any arrhythmia should prompt immediate assessment of serum digoxin levels and renal function ^[1]A1c.

Hyperkalemia

Hyperkalemia is a hallmark of acute digoxin toxicity and a major predictor of mortality. The expert consensus statement from Hack et al. (2024) highlights that a serum potassium >5.0 mEq/L in the setting of acute digoxin overdose is an indication for immediate administration of digoxin-specific antibody fragments (Fab) ^[1]A1c. In chronic toxicity, hyperkalemia is less common but still carries prognostic significance; the median potassium in fatal chronic cases was 5.1 mEq/L ^[41]B3b. The mechanism involves inhibition of Na+/K+ ATPase, leading to extracellular potassium shift ^[53]D5.

Drug Interactions and Precipitation of Toxicity

Several drug interactions increase the risk of digoxin toxicity. Macrolide antibiotics (erythromycin, clarithromycin) inhibit P-glycoprotein–mediated efflux, raising serum digoxin levels; a population-based study found that clarithromycin use in older digoxin users increased the risk of sudden death ^[25]B3b. Amiodarone can cause significant fluctuations in digoxin levels, with one case report showing daily swings from 0.9 to 2.93 ng/mL after amiodarone initiation ^[39]C4. Sennosides, commonly used for constipation, interact with digoxin; a nested case-control study in heart failure patients found a 1.5-fold increased risk of digoxin toxicity hospitalization (adjusted OR 1.49, 95% CI 1.02–2.17) with concurrent sennoside use ^[50]B3b. Clarithromycin also precipitated digoxin toxicity in a patient with dehydration and renal dysfunction ^[40]C4.

Renal Impairment and Age

Renal insufficiency is a major risk factor for digoxin toxicity because digoxin is primarily excreted unchanged by the kidneys ^[73]D5. In the elderly, low lean body mass, female sex, and decreased glomerular filtration rate contribute to higher serum levels ^[73]D5. A study of older Thai patients with heart failure and atrial fibrillation reported that digoxin use was associated with a higher risk of all-cause mortality (HR 1.44, 95% CI 1.02–2.04) and heart failure rehospitalization ^[15]C4. In a retrospective series of 47 patients with supratherapeutic digoxin levels, those who received digoxin-Fab had a lower median heart rate (<51/min) and higher serum potassium, but the decision to treat was often based on clinical judgment rather than strict thresholds ^[19]B2b.

Maternal and Fetal Complications

Digoxin is used transplacentally to treat fetal tachyarrhythmias, but maternal toxicity is a concern. In a series of 38 women treated with oral digoxin for fetal tachycardia, maternal side effects occurred in 31.6%, including nausea, vomiting, and ECG changes; digoxin levels >2.0 ng/mL were associated with a higher risk of maternal complications ^[10]C4. No maternal deaths were reported, but close monitoring of serum levels and ECG is recommended ^[10]C4.

Special Populations: AL Amyloidosis

The use of digoxin in systemic light-chain (AL) amyloidosis is historically contraindicated due to increased sensitivity and toxicity. In a contemporary cohort of 107 patients with AL amyloidosis who received digoxin between 2000 and 2015, significant arrhythmias developed in 11% (almost exclusively in those with advanced cardiac involvement), and 8% died from arrhythmia ^[18]C4. The authors recommend cautious use with dose reduction and frequent monitoring of serum levels and renal function.

Monitoring and Prevention of Complications

Current monitoring recommendations are insufficient to prevent toxicity; the National Poison Control Center data show that digoxin causes more deaths than lithium or warfarin, yet routine monitoring is not enforced ^[8]D5. The expert consensus advocates for frequent serum digoxin measurements to maintain levels between 0.5 and 1.0 ng/mL because higher levels lead to increased morbidity and mortality without additional benefit ^[1]A1c[8]D5. In the DORA study (ATOM-1), anti-digoxin Fab effectively bound free digoxin, but improved clinical outcomes did not always correlate with biochemical changes in chronic toxicity ^[36]C4.

Summary of Key Risks

• Mortality: 18–36 deaths/year in the US ^[8]D5.
• Arrhythmias: Bradycardia, heart block, bidirectional VT ^[73]D5.
• Hyperkalemia: >5.0 mEq/L is a critical threshold for Fab therapy ^[1]A1c.
• Drug interactions: Macrolides ^[25]B3b, amiodarone ^[39]C4, sennosides ^[50]B3b increase toxicity.
• Renal function: Key determinant of clearance; elderly at highest risk ^[15]C4[73]D5.
• AL amyloidosis: High risk of arrhythmic death ^[18]C4.

Even with optimal management, the prognosis of digoxin toxicity depends on the interplay of easily identified clinical and laboratory factors. The natural history of untreated toxicity can be fatal, but prompt recognition and antidote administration improve survival ^[35]D5.

Natural History and Mortality

Without treatment, digoxin toxicity progresses to life-threatening arrhythmias ^[35]D5. In a systematic review of 84 patients with digoxin poisoning, the mortality rate was approximately 7% (6 fatalities) ^[51]A1c. Digoxin-specific antibody fragments reduce mortality ^[35]D5, but high-risk patients still die. In a case-control study, 13 fatalities occurred over 7 years; despite appropriate Fab therapy in 7 of these cases, death ensued ^[41]B3b.

Prognostic Predictors

Serum potassium is the single most validated predictor. A pre-treatment potassium ≥5.0 mEq/L identified fatality with 92% sensitivity (95% CI 67-99) ^[41]B3b. The combination of bradycardia plus hyperkalemia was present in 86% of deaths despite appropriate Fab administration ^[41]B3b. Diabetes increases the risk of toxicity: in the DIG trial, suspected toxicity occurred in 6.5% of diabetic patients vs 5.8% of non-diabetic patients, and hospitalization for toxicity was 1.4% vs 0.8% ^[21]A1b. Renal impairment further elevates risk ^{[21]A1b[41]B3b}. Co-prescription of TMP-SMX raises the 30-day risk of a hospital encounter for digoxin toxicity nearly 6-fold (RR 5.71; NNH 256) ^[4]B2b.

Prognostic Implications

These factors guide risk stratification: a patient with hyperkalemia, bradycardia, renal impairment, and diabetes carries the highest risk of mortality and warrants urgent Fab therapy. The EXTRIP workgroup recommends against the use of extracorporeal treatments in any form for digoxin toxicity ^[51]A1c.

Prognostic Factors Summary

Pearl: The combination of bradycardia and hyperkalemia (K⁺ ≥5.0 mEq/L) in chronic digoxin toxicity is a marker of near-certain fatality without immediate Fab therapy, do not delay.

Prognosis after digoxin toxicity is heavily influenced by patient age and comorbidities, making special populations a central consideration in both prevention and management.

Elderly

Elderly patients account for the vast majority of digoxin toxicity diagnoses, 88% are over age 65 ^[52]B2b. Age-related decline in renal function, reduced lean body mass, and polypharmacy create a perfect storm for drug accumulation. Hospitalization itself is a potent risk factor: patients hospitalized in the prior 2 months have a 4.25-fold increased risk of subsequent digoxin toxicity (IRR 4.25; 95% CI 1.95-9.27) ^[22]B2b. Concurrent use of negative chronotropes (beta-blockers, calcium channel blockers) and potassium-wasting diuretics is common and amplifies toxicity ^[19]B2b.

Digoxin immune Fab (DIF) is administered in roughly one-fifth of cases ^[52]B2b. Predictors of DIF use include hyperkalemia (OR 2.4), arrhythmia (OR 3.6), acute renal failure (OR 2.1), and suicidal intent (OR 3.7) ^[52]B2b. In chronic toxicity, DIF is given more often when heart rate is <51/min or serum potassium >5.0 mmol/L ^[19]B2b. However, indications remain inconsistent; some elderly patients with levels >10 ng/mL are managed supportively without Fab ^[76]C4. Regular monitoring of digoxin levels, not just during toxic episodes, is essential, especially in patients with dementia or cognitive impairment who cannot reliably report symptoms ^[76]C4. Unusual presentations such as phantosmia (floral scent hallucinations) and photopsia have been reported and should prompt consideration of toxicity ^[57]C4.

Immunocompromised

Drug-drug interactions in HIV-positive patients on antiretroviral therapy pose a specific risk. Ritonavir, a protease inhibitor, can markedly increase digoxin concentrations. The first case of digoxin toxicity due to ritonavir interaction was reported in 2003, and a subsequent case in a 51-year-old man highlights the combination of drug interaction and renal impairment ^[75]C4. As the HIV population ages and digoxin use may increase for atrial fibrillation or heart failure, clinicians must monitor digoxin levels closely when protease inhibitors are co-prescribed.

Prevention

Primary prevention focuses on avoiding digoxin in high-risk elderly patients with impaired renal function or polypharmacy, using the lowest effective dose, and monitoring renal function and electrolytes regularly. Secondary prevention after a toxicity episode includes permanent discontinuation of digoxin in most cases, patient education about symptom recognition, and avoidance of interacting drugs (macrolides, calcium channel blockers, diuretics, omeprazole) ^{[25]B3b[19]B2b[76]C4}. Routine monitoring of digoxin levels, particularly after hospitalization, can prevent recurrent toxicity ^{[22]B2b[76]C4}.

Pearl: In elderly patients, a serum digoxin level within the therapeutic range does not rule out toxicity, electrolyte disturbances (hypokalemia, hypomagnesemia) and drug interactions can precipitate toxicity at any level; clinical judgment must guide management ^[57]C4.